title: PARP inhibitor combination therapy.
abstract: In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality. However, PARP inhibition also shows considerable promise when used together with other therapeutic agents. Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies.
authors.affiliation: The CRUK Gene Function Laboratory, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
authors.forename: Amy
authors.initials: A
authors.lastname: Dréan
authors.affiliation: The CRUK Gene Function Laboratory, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. Electronic address: Chris.Lord@icr.ac.uk.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Lord
authors.affiliation: UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USA. Electronic address: Alan.Ashworth@ucsf.edu.
authors.forename: Alan
authors.initials: A
authors.lastname: Ashworth
mesh_terms: D000818:Animals; D004338:Drug Combinations; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism
chemical_list: D004338:Drug Combinations; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases
keywords: BRCA1; BRCA2; Drug combinations; PARP inhibitor